These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 18084154)

  • 1. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 2. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
    Malizzia LJ; Hsu A
    Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
    Figlin RA
    Nat Clin Pract Oncol; 2008 Oct; 5(10):601-9. PubMed ID: 18607393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status.
    Jafri M; Douis H; Porfiri E
    Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704
    [No Abstract]   [Full Text] [Related]  

  • 6. Temsirolimus for advanced renal cell carcinoma.
    Figlin RA
    Clin Adv Hematol Oncol; 2007 Nov; 5(11):893. PubMed ID: 18185488
    [No Abstract]   [Full Text] [Related]  

  • 7. Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.
    Gerullis H; Bergmann L; Maute L; Eimer C; Otto T
    Cancer Chemother Pharmacol; 2009 May; 63(6):1097-102. PubMed ID: 18818922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temsirolimus in patients with advanced renal cell carcinoma: an overview.
    Bhatia S; Thompson JA
    Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.
    Paterson C; Jones RJ
    Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma.
    Rodríguez Faba O; Breda A; Rosales A; Palou J; Algaba F; Maroto Rey P; Villavicencio H
    Eur Urol; 2010 Aug; 58(2):307-10. PubMed ID: 20347211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecule of the month. Temsirolimus.
    Drug News Perspect; 2007; 20(6):406. PubMed ID: 17925894
    [No Abstract]   [Full Text] [Related]  

  • 14. [ASCO 2006: temsirolimus increases survival].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
    Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
    Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
    De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
    Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.
    Boni JP; Hug B; Leister C; Sonnichsen D
    Semin Oncol; 2009 Dec; 36 Suppl 3():S18-25. PubMed ID: 19963096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of mTOR inhibitor side effects.
    Creel PA
    Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temsirolimus in renal cell carcinoma.
    Otto T; Eimer C; Gerullis H
    Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temsirolimus for advanced renal cell carcinoma.
    Bergmann L; Maute L; Guschmann M
    Expert Rev Anticancer Ther; 2014 Jan; 14(1):9-21. PubMed ID: 24313573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.